Делсия

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Делсия

Property Description
Active ingredients Drospirenone and Ethinyl Estradiol
Form Film-coated tablet
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Prevention of pregnancy
Origin Synthetic steroid hormones

Делсия: Definition and Pharmacological Classification

Делсия is a medicinal product classified as a Combined Hormonal Contraceptive (CHC), representing a systemic agent used primarily for the prevention of pregnancy. This combination product is defined by its structure containing two distinct synthetic steroid hormones, a strategy used for efficacy in fertility control. The oral administration route and the standard dosage form of a film-coated tablet establish the product's delivery method. The comprehensive pharmacological identity is established by its function as an inhibitor of the female reproductive cycle, a mechanism utilized for reliable contraception.

Composition and Origin: The Active Ingredients

The product's efficacy is rooted in its dual composition, specifically containing the active ingredients Drospirenone and Ethinyl Estradiol. Both compounds are synthetic in origin and are structurally designed steroid hormones. Drospirenone is a unique synthetic progestogen, distinguished by its inherent antimineralocorticoid and antiandrogenic properties, giving it a pharmacological profile that resembles natural progesterone. This specific progestin component possesses hormonal activity that can influence fluid balance. The product's distinctive features include the combination of Drospirenone with Ethinyl Estradiol, which places it within the category of fourth-generation progestin formulations.

General Purpose of the Hormonal Combination

The definitive and general purpose of the Делсия formulation is the reliable prevention of pregnancy through multiple, coordinated physiological actions. The medicine is typically used by women of childbearing age seeking a highly effective, prescription-only method of contraception. The combined hormonal approach works primarily by suppressing the body's natural release of hormones, which prevents the maturation and release of an egg. Furthermore, the hormones induce local changes, such as thickening the cervical mucus and altering the uterine lining. This established multi-target mechanism ensures the medicine functions as a potent and dedicated contraceptive agent.

What side effects are possible with Делсия?

The safety profile for the combined hormonal oral contraceptive branded as Делсия (containing drospirenone and ethinyl estradiol) is primarily structured around the risks associated with combination hormonal use, particularly thromboembolic events.

Serious and Clinically Significant Risks

The most serious documented risk is the potential for venous and arterial thromboembolic events (VTE/ATE), which include deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Regulatory documents indicate that drospirenone-containing contraceptives may be associated with a higher risk of VTE compared to products containing certain other progestins. This risk is notably elevated in women who smoke and are over the age of 35. Discontinuation is mandated if a thrombotic event occurs.

Another specific safety concern is the risk of hyperkalemia (high potassium levels in the blood) due to drospirenone's anti-mineralocorticoid activity. Use is contraindicated in individuals with conditions that predispose to hyperkalemia, such as renal or adrenal insufficiency. Monitoring of serum potassium is advised for women on concomitant long-term medication known to increase potassium.

Serious liver issues, including benign or malignant liver tumors and hepatic impairment, are also documented contraindications. The drug must be discontinued if jaundice develops.

Common Adverse Reactions

Adverse reactions reported as common (occurring in ge1% of users) include breast pain or tenderness, headache/migraine, nausea, irregular uterine bleeding or spotting, weight changes, and mood alterations like depression or emotional lability.

Overdose and Emergency Response

The regulatory profile for overdosage with the combined hormonal contraceptive Делсия (Drospirenone and Ethinyl Estradiol) outlines the expected clinical manifestations and the necessary emergency response documented by official health authorities.

Overdose Entity Map Official Regulatory Statement
Documented Manifestations: Acute overdosage is documented to present primarily with nausea, vomiting, and vaginal bleeding (withdrawal bleeding).
Severity Classification: Overdosage with this combination is generally classified in regulatory documents as not expected to be serious or life-threatening.
Required Action: Seek emergency medical attention immediately upon the suspicion of overdosage. Contact a Poison Help line or emergency room at once.
Management Procedure: Management of overdose is limited to symptomatic and supportive treatment, as official documents confirm that no specific antidote is known.

The official overdose information defines the expected clinical course as having low acute toxicity, typically resulting in temporary gastrointestinal and reproductive system symptoms. Guidance from regulatory authorities establishes the primary action: seeking immediate medical evaluation for professional monitoring and supportive care. This mandated emergency response is required to manage documented symptoms and ensure patient stability following accidental or intentional exposure beyond the prescribed dose. Regulatory labeling also notes that withdrawal bleeding may be observed in pre-pubertal females who have inadvertently ingested the medication.

Therapeutic Uses of Делсия

What Делсия Treats: Main Uses and Benefits

This medication is commonly used across primary therapeutic domains, particularly in conditions characterized by periods of heightened symptoms that create noticeable physiological strain.

The primary role of the medication is to serve as a form of contraception for women of reproductive age. It is applied in situations involving symptomatic support for pregnancy prevention and assists in establishing predictable menstrual cycle patterns. Beyond its primary use, it is considered relevant for managing symptoms that interfere with daily functioning seen in Premenstrual Dysphoric Disorder (PMDD) and moderate acne vulgaris, as well as specific symptoms related to physical discomfort.

“The medicine may assist with a more manageable experience of day-to-day functioning during these heightened symptomatic periods.”

This medication helps address symptom clusters that interfere with daily comfort, contributing to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Premenstrual Distress The medication is applied in conditions presenting with symptoms related to heightened physiological activity, such as intense mood swings, anxiety, and cyclical bloating associated with PMDD.

Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

The eligibility for using Делсия (Drospirenone / Ethinyl Estradiol) is strictly defined by regulatory authorities, with use permitted for females of reproductive potential seeking contraception.

Contraindications and Non-Eligibility

Use of this medicine is absolutely contraindicated in individuals with a number of specific conditions, as outlined in official labeling:

  • Vascular and Thrombotic Risk: Contraindicated in individuals with a high risk or history of arterial or venous thrombotic diseases, including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cerebrovascular Disease, or Coronary Artery Disease.
  • Age and Smoking: Prohibited for females over 35 years old who smoke, due to a significantly increased risk of serious cardiovascular events.
  • Organ Function: Contraindicated in individuals with known renal impairment or adrenal insufficiency, as well as those with active liver disease or liver tumors.
  • Hormone-Sensitive Conditions: Prohibited for those with current or history of breast cancer or other hormone-sensitive malignancies.
  • Pregnancy Status: Contraindicated during known or suspected pregnancy.

Restricted and Conditional Use

Population/Condition Regulatory Status
Lactation/Breastfeeding Not generally recommended (restricted).
Major Surgery/Immobilization Use must be discontinued at least four weeks before and two weeks after major surgery.
Age of Use Contraindicated before menarche and not indicated for use in the geriatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Drospirenone and Ethinyl Estradiol (Делсия) is officially documented to categorize combinations based on the risk of serious adverse outcomes or loss of contraceptive efficacy. Regulatory information emphasizes interactions linked to metabolic clearance and pharmacodynamic reinforcement.

Contraindicated Combinations

Co-administration is prohibited with specific combination drug products used to treat Hepatitis C (e.g., ombitasvir/paritaprevir/ritonavir pm dasabuvir), due to the documented risk of significant liver enzyme (ALT) elevations. Additionally, tobacco smoking is contraindicated in females over 35 years of age due to the heightened risk of serious cardiovascular events.

Clinically Significant Drug Interactions

Interaction Type Interacting Substances (Examples) Official Outcome
Reduced Exposure Hepatic enzyme inducers (e.g., Rifampin, Phenytoin, St. John's wort) Decreased plasma concentrations, risking loss of contraceptive effectiveness.
Increased Exposure Strong CYP3A4 inhibitors (e.g., Ketoconazole, Clarithromycin) Increased Drospirenone exposure, raising the potential for hyperkalemia.
Pharmacodynamic Risk Potassium-sparing agents (e.g., ACE inhibitors, ARBs, long-term NSAIDs) Additive risk of hyperkalemia due to Drospirenone's antimineralocorticoid activity.

Population-Specific Constraint

The risk of hyperkalemia from these pharmacodynamic interactions is specifically relevant for patients with pre-existing conditions such as renal impairment, hepatic impairment, or adrenal insufficiency.

Mechanism of Action

Делсия (Delcia) is a human IgG2 monoclonal antibody. Its mechanism of action involves highly specific binding to the soluble cytokine, Receptor Activator of Nuclear factor Kappa B Ligand (RANKL). RANKL is the principal physiological mediator of osteoclast formation, function, and survival. The binding of Delcia to RANKL prevents the ligand from interacting with its cognate receptor, RANK, located on the surface of pre-osteoclast cells and mature osteoclasts. This targeted inhibition effectively blocks RANK signaling, which is essential for osteoclastogenesis. The resulting blockade leads to decreased activation, impaired differentiation, and accelerated apoptosis of osteoclasts. The suppression of osteoclast activity and lifespan ultimately decreases the rate of bone resorption. This physiological modulation leads to a net gain in bone mineral density.

Dosage and Administration Information

How to Use Делсия

Делсия is a medication administered exclusively through the oral route, employing a daily, continuous, cyclic dosing schedule designed to maintain consistent hormone levels. The medication is delivered in the form of a film-coated tablet.

Standard Administration Cycle

The standard regimen involves taking one tablet once daily over a continuous 28-day period at the same time every day. The standard 28-day pack consists of 24 active tablets (containing Drospirenone 3 mg and Ethinyl Estradiol 0.02 mg) followed by four inert (placebo) tablets.

The core procedural instruction is that tablets must be consumed in the order directed on the blister pack. A new pack must be started immediately after the last tablet of the previous 28-day cycle is finished, with no scheduled break in administration. The tablets may be taken without regard to meals.

Administration Principle Labeled Instruction
Dosing Pattern One tablet taken daily over a 28-day cycle (24 active, 4 inert).
Timing Rule Must be taken at the same time every day.
Initiation Options include the Day 1 Start or the Sunday Start method.

Procedural Requirements

Full effectiveness is not established until after the first seven consecutive days of active tablet administration. Age-group administration rules specify that use is limited to females who have achieved menarche (the onset of menstruation) and is not indicated for postmenopausal women. Furthermore, specific instructions detailing the procedure for handling missed active tablets must be followed, as this may necessitate the temporary use of a non-hormonal backup method to maintain the intended use protocol.

Recent Clinical Evidence

Evidence Overview: Studies for Pregnancy Prevention

Research exploring the medicine's primary application—the prevention of pregnancy—primarily relies on observational studies and regulatory Phase 3 trials. This research examined how researchers measured the rate of pregnancy, a standardized calculation known as the Pearl Index, and monitored outcomes such as cycle regularity in women of reproductive age. Findings describe patterns consistent with regulatory documentation for this class of medicine. However, the effectiveness measure is highly sensitive to user adherence (consistency of use), and comparative evidence against all modern contraceptive methods is not always fully documented in recent controlled trials.

Research Evidence for Symptomatic Applications

The research for Premenstrual Dysphoric Disorder (PMDD) consists of randomized, double-blind, placebo-controlled trials (RCTs). These studies examined episodic changes in symptom intensity, including those linked to mood swings and physical discomfort, using validated tools like the Daily Record of Severity of Problems (DRSP) score in women with clinically confirmed PMDD. Separately, the medicine was studied for moderate acne vulgaris using controlled trials. Research examined outcomes related to physical discomfort by tracking changes in acne lesion counts (both inflammatory and non-inflammatory) and overall skin improvement using global assessments in women with moderate acne.

Evidence Gaps and Uncertainty in the Research

A key limitation in the symptomatic research is that controlled trials (for PMDD and acne) involved limited follow-up durations (e.g., typically three cycles for PMDD). This means controlled trials provide limited information for long-term outcomes regarding sustained symptomatic measurements. Furthermore, the research applies only to moderate acne; data for treating severe, nodular, or cystic acne remain insufficient. Its application for the less severe condition, Premenstrual Syndrome (PMS), was not the subject of these primary trials.

Key Studies & References A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris

Frequently Asked Questions (FAQ)

Common questions about Делсия (FAQ)

Q: What is the most important thing to know before starting Делсия?

Official product information highlights a BOXED WARNING regarding the increased risk of serious blood clots and cardiovascular events, particularly in women over 35 who smoke. Regulatory documents also detail contraindications, which are conditions where use of the medicine is generally prohibited. These contraindications are related to a history of blood clots, certain organ diseases, and specific malignancies.

Q: Is Делсия a long-term treatment or short-term?

Regulatory documents state that Делсия is administered using a continuous daily administration schedule, meaning there are no breaks between cycles for ongoing use. While the drug is designed to be taken continuously, the total duration of treatment is typically determined by the prescribing healthcare provider based on the individual's needs.

Q: What does 'Делсия treats' mean in simple terms?

Делсия has multiple approved uses as described in official indications. Its primary purpose is the prevention of pregnancy. It is also officially indicated for treating symptoms of Premenstrual Dysphoric Disorder (PMDD) and managing moderate acne vulgaris in women who have chosen to use an oral contraceptive.

Q: How quickly should I expect to see an effect from Делсия?

The onset of the drug's action depends on its purpose. For contraceptive use, effectiveness is generally considered reliable after the first seven days of continuous active tablet use. For symptomatic uses like PMDD or acne, clinical studies often assess significant changes after a longer period, usually around two to three treatment cycles.

Q: Does Делсия interact with common over-the-counter pain relievers?

Official labeling describes a potential interaction when Делсия is used long-term with NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), which are common pain relievers. This combination is associated with an increased risk of hyperkalemia (high potassium levels in the blood), particularly in individuals with pre-existing organ conditions.

Q: Is Делсия available in different strengths?

Regulatory listings confirm that the product, Делсия, is available in one specific strength. This approved composition contains 3 milligrams of Drospirenone and 0.02 milligrams of Ethinyl Estradiol per active tablet.

Q: Does Делсия cause drowsiness or affect driving?

Official data lists common nervous system effects, such as headache and mood changes, which some users experience. While the label does not contain a specific warning that prohibits driving, any medication that affects mood or the nervous system may potentially alter responsiveness, as is generally the case with systemic medications.

Q: Is Делсия considered a 'controlled' substance?

According to regulatory documents, Делсия is not classified as a controlled substance. This means it is not subject to the specific regulations governing drugs with high potential for abuse or dependence, such as those listed under the U.S. Controlled Substances Act.

Q: Is it possible to take Делсия with vitamins or supplements?

Official documents specifically warn that combining Делсия with the supplement St. John’s wort may reduce the medication's effectiveness in preventing pregnancy. While other vitamins and common supplements are generally not listed as formal interactions, it is generally necessary to disclose all co-administered products.

Q: What is the general safety classification of Делсия from regulatory bodies?

The high-level safety profile is primarily defined by the serious risks associated with this class of hormonal contraceptives. Regulatory authorities include a BOXED WARNING for serious cardiovascular risk and list multiple absolute contraindications (prohibitions on use) related to blood clots and certain health conditions.

Q: What happens if I stop taking Делсия suddenly?

According to official labeling, stopping the medication will generally result in a rapid return to pre-treatment fertility levels and the resumption of the natural menstrual cycle. The medication is required to be discontinued immediately if specific serious adverse events, such as a suspected blood clot, are experienced.

Q: Is there a known effect of Делсия on blood pressure?

Yes, regulatory documents state that a rise in blood pressure has been reported in women taking oral contraceptives like Делсия. Patients with pre-existing high blood pressure (hypertension) are often carefully monitored during treatment.

Q: Are there any known interactions between Делсия and alcohol?

Alcohol is not listed as a formal drug interaction in the same way as prescription medications. However, because Делсия is metabolized (processed) by the liver, and excessive alcohol consumption can affect liver function, some caution may be suggested.

Q: What is the risk of dependence or addiction with Делсия?

Regulatory documentation explicitly states that there is no known evidence of drug abuse or dependence associated with the use of Делсия. This medication is not considered to have a potential for addiction.

Q: Why do official documents list so many potential interactions for Делсия?

Official documents list many interactions because the active ingredients are processed by liver enzymes (CYP3A4), making the drug susceptible to interference from many other medications. Furthermore, the Drospirenone component has unique antimineralocorticoid activity which affects potassium levels, adding another pathway for interaction with certain drug classes.

Q: Are there any specific monitoring tests required when using Делсия?

The official label indicates that monitoring of serum potassium is generally advised for patients taking Делсия in combination with other medications that are known to increase potassium. This is due to the unique activity of the Drospirenone component.

Q: Does Делсия affect fertility or reproductive health?

The regulatory information indicates that after stopping the medication, ovulation and normal fertility generally return shortly after discontinuation. The medication does not cause permanent infertility.

Q: Are there any official warnings about combining Делсия with herbal remedies?

Regulatory guidance suggests an awareness that some herbal products can affect the levels of the active ingredients in the body. The official drug label specifically warns that co-administration with the herbal remedy St. John’s wort may reduce the drug's effectiveness.

Q: What is the typical duration of treatment with Делсия for its main use?

The product is designed for continuous treatment without planned breaks between cycles, suggesting it can be taken for extended periods. However, the total duration of treatment is typically determined by the prescribing healthcare provider based on the ongoing needs of the individual.

Q: What are the pregnancy and breastfeeding safety categories for Делсия?

Official documentation states that use is contraindicated (prohibited) during known or suspected pregnancy. For breastfeeding, the medication is generally not recommended in the first few weeks after childbirth, as hormonal contraceptives may decrease the production of breast milk.

Q: Has Делсия been approved in major international markets?

Yes, the product has been reviewed and approved by major regulatory authorities in several international markets. This includes organizations such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: What are the signs that Делсия is starting to work for me?

Studies reviewed by regulatory bodies describe how effectiveness was measured for symptomatic uses. For PMDD, effectiveness was measured by improvement in the Daily Record of Severity of Problems (DRSP) score. For acne, it was measured by a reduction in the number of inflammatory and non-inflammatory lesions.

Q: Can I crush or split the Делсия tablets?

Official instructions state that the medication is a film-coated tablet which must be consumed whole and in the order directed on the blister pack. The official instructions for administration do not provide information on crushing or splitting the tablets.

Q: Does Делсия contain lactose or gluten?

The inactive ingredients section of the official label confirms that lactose is a component of the tablets. Official regulatory documents typically do not list information regarding gluten content.

Q: How is Делсия eliminated from the body?

Official pharmacology information states that the active ingredients are processed by the body and primarily eliminated as metabolites. The final excretion pathway involves both urine and feces.

Q: Are there any known withdrawal symptoms if Делсия is stopped?

Regulatory documents do not specifically list 'withdrawal symptoms' upon stopping the medication. However, discontinuation does lead to the cessation of hormonal effects, which is expected to result in the return of ovulation and the resumption of the menstrual cycle.

How should Делсия be stored and disposed of?

How to Store and Dispose of Delsia (Drospirenone and Ethinyl Estradiol)

The official storage requirements for this medication are defined to maintain stability and effectiveness.

Storage Requirement Condition
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Keep away from excessive heat and moisture.
Packaging Keep tablets in the original container/blister pack.
Child Safety Must be stored out of the sight and reach of children.

Unused or expired Delsia must be disposed of according to federal and local regulations. The preferred method is using a drug take-back program. If this is unavailable, mix the tablets with an undesirable substance (e.g., dirt) in a sealed bag before placing it in the household trash. Do not flush this medicine down the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Делсия found in:

A-Z Index: